title: From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.
abstract: BACKGROUND
  Biologics are widely used in the treatment of psoriasis and psoriatic arthritis.
  
  
  OBJECTIVE
  Our aim was to arrive at a consensus on the kind of monitoring and the vaccinations that should be performed before and during biologic therapy.
  
  
  METHODS
  Medical literature and data presented at meetings were reviewed and a consensus conference was held by members of the Medical Board of the National Psoriasis Foundation.
  
  
  RESULTS
  Consensus was established on monitoring and vaccination practices that included discussion and recognition of variations in those practices. History, physical examination, chemistry screen with liver function tests, complete blood cell count, and platelet count and tuberculosis testing are widely obtained at baseline and with variable frequencies thereafter. Patients treated with efalizumab have platelet counts checked more often; liver function tests are repeated more frequently in patients treated with infliximab; patients taking tumor necrosis factor blockers undergo tuberculosis testing more often; and patients treated with alefacept have CD4 counts checked approximately every 2 weeks. Avoidance of live vaccines during biologic therapy and administration of essential vaccines before biologic therapy were discussed, although vaccination is performed only to a variable degree. There was no consistency in the measurement of antinuclear antibodies among the experts.
  
  
  CONCLUSIONS
  There are few evidence-based studies on monitoring practices for patients with psoriasis taking biologic therapies.
  
  
  CONCLUSIONS
  In patients taking biologic therapies for psoriasis, monitoring of blood chemistries, blood counts, CD4 counts, antinuclear antibodies, tuberculin skin tests, history, and physical examination may be warranted depending on the particular therapy and the particular patient. Vaccination practices are also addressed.
authors.affiliation: Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA. getinfo@psoriasis.org
authors.forename: Mark
authors.initials: M
authors.lastname: Lebwohl
authors.forename: Jerry
authors.initials: J
authors.lastname: Bagel
authors.forename: Joel M
authors.initials: JM
authors.lastname: Gelfand
authors.forename: Dafna
authors.initials: D
authors.lastname: Gladman
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: Gordon
authors.forename: Sylvia
authors.initials: S
authors.lastname: Hsu
authors.forename: Robert E
authors.initials: RE
authors.lastname: Kalb
authors.forename: Alexa Boer
authors.initials: AB
authors.lastname: Kimball
authors.forename: Neil J
authors.initials: NJ
authors.lastname: Korman
authors.forename: Gerald G
authors.initials: GG
authors.lastname: Krueger
authors.forename: Philip
authors.initials: P
authors.lastname: Mease
authors.forename: Warwick L
authors.initials: WL
authors.lastname: Morison
authors.forename: Amy
authors.initials: A
authors.lastname: Paller
authors.forename: David M
authors.initials: DM
authors.lastname: Pariser
authors.forename: Christopher
authors.initials: C
authors.lastname: Ritchlin
authors.forename: Bruce
authors.initials: B
authors.lastname: Strober
authors.forename: Abby
authors.initials: A
authors.lastname: Van Voorhees
authors.forename: Gerald D
authors.initials: GD
authors.lastname: Weinstein
authors.forename: Melodie
authors.initials: M
authors.lastname: Young
authors.forename: Liz
authors.initials: L
authors.lastname: Horn
mesh_terms: D000974:Antibodies, Antinuclear / Q000097:blood; D001688:Biological Products / Q000627:therapeutic use*; D005582:Foundations; D006403:Hematologic Tests; D006801:Humans; D008111:Liver Function Tests; D008499:Medical Records; D010808:Physical Examination; D011159:Population Surveillance / Q000379:methods*; D011565:Psoriasis / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D014374:Tuberculin Test; D014481:United States; D014611:Vaccination
chemical_list: D000974:Antibodies, Antinuclear; D001688:Biological Products